Novimmune SA announced today that it has signed an international research collaboration agreement with Baxalta Incorporated. This is the first collaboration utilizing Novimmune's new kappa-lambda bispecific antibody technology.
The proprietary platform generates fully human antibodies which target two specific binding sites with one antibody. “The kappa-lambda platform is exactly the right technology for therapy areas which need a bispecific antibody that is as close to a natural human antibody as you can get,” said Novimmune CEO Jack Barbut.
Bispecific antibodies currently used in biopharmaceutical applications have been constructed using chemical linkers, non-human material, antibody fragments or forced engineering, he said.
“Our kappa-lambda antibodies are allowed to assemble naturally,” said Head of Research Nicolas Fischer. “So, they have promising development and safety characteristics such as a longer half-life, increased stability and a lower risk of provoking an unwanted reaction in patients.”
Financial terms of the deal were not disclosed.
Baxalta (NYSE: BXLT) is a newly established global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology.
Novimmune SA is a Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.
(SK)
Please login or sign up to comment.
Commenting guidelines